Pampee Young Archives

Pampee Young, MD, PhD, left, Sarika Saraswati, PhD, and colleagues are studying the different ways fibroblasts function following tissue injury.

Cellular engines of wound repair have distinct roles

Aug. 8, 2019—Vanderbilt investigators have discovered that, in contrast to prevailing dogma, fibroblasts are not all alike; instead, they have distinctive functions following tissue injury.

Young named chief medical officer of American Red Cross

Jan. 4, 2018—Vanderbilt’s Pampee Young, MD, PhD, has been named chief medical officer of the American Red Cross.

Surgical training enhances VUMC, Fort Campbell bond

Apr. 28, 2016—During a deployment as a military surgeon more than a decade ago, Vanderbilt University Medical Center’s Tim Nunez, M.D., felt ill prepared to perform complex trauma surgeries for an Iraqi family caught in a fire fight, but he's now committed to helping military personnel become better trained for these types of emergencies.

Healing without scarring

Oct. 16, 2015—Drugs that inhibit the Wnt signaling pathway can regenerate injured skin and may be useful in treating fibromatosis, degenerative joint disease and cancer.

Boosting cell-based heart repair

May. 15, 2015—A metabolic change in adult stem cells makes them less “fit” for regenerative heart therapies, suggesting that strategies to prevent this response may boost the therapeutic usefulness of the cells.

Kids more likely to react to blood transfusions

May. 4, 2015—Pediatric patients have a significantly higher incidence of transfusion reactions compared to adults, according to a study by Vanderbilt University researchers.

Target for atherosclerosis therapies

Dec. 17, 2014—A newly identified “atheroprotective” gene is a tool for exploring plaque pathophysiology and may be a good target for therapies to slow atherosclerosis progression.

Factor’s yin-yang tumor effects

Jun. 10, 2013—A factor produced by most malignant cells can both promote and inhibit tumor growth – an insight that is critical to using cancer drugs developed to block this factor.